Is there anyone that doesn't believe that if the Critical trial in Brazil has 4 doses and makes the endpoints mortality or days in hospital that LL won't hit the endpoints with stat sig?
Am I happy that we have to sit through another trial? No but when the trials were designed last year Covid was new so getting it exactly right on the first try would have been lucky, not smart which is why I don't blame NP. Things could have been done differently but now we have the data to know what our endpoints and dosing should be.
If the Critical trial doesn't have 4 doses then I will agree that the majority of the team needs to be fired but if they do then I think we'll hit endpoints with stat sig and all of this will be behind us. There won't be any excuses about a "subgroup" when Critical patients are the only patients in the trial and you can see the clear drop off in mortality from when people stopped receiving LL in CD12.
News 
Market Data 
Discover 
